Observational Study in Japanese Type 2 Diabetes Patients

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to address the gap in the literature related to changing treatment regimen or formulation between different types of insulin, and how this change impacts quality of life, adherence, individual patient treatment satisfaction and glycemic control.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Inpatients or outpatients with type 2 diabetes, aged 20 years or older, on insulin therapy who have planned to change insulin therapy during the registration period of the study

• Patients who have provided written informed consent to participation in the study after receiving explanations about the objective and other details of the study

• Patients who have received the same insulin therapy for 3 months or longer before informed consent. (i.e. receiving the same type of insulin preparation at the same dosing frequency regardless of insulin dose)

Exclusion Criteria:

• Patients who have planned to discontinue insulin therapy

• Patients incapable of completing the ITR-QOL, DTSQ and patient's questionnaire based on their self-ratings

• Patients with type 1 diabetes

• Patients who have used CSII or have planned to switch to CSII(continuous subcutaneous insulin infusion )

• Patients with poor treatment compliance as determined by their investigators based on the treatment history